January 2015 - Biowebspin | Biowebspin
Logo Biowebspin

Archives January 2015 - Biowebspin

Challenges in exploiting open innovation’s full potential in the food industry with a focus on small and medium enterprises (SMEs)

Challenges in exploiting open innovation’s full potential in the food industry with a focus on small and medium enterprises (SMEs)

  Biowebspin, January 28th, 2015 Challenges in exploiting open innovation's full potential in the food industry with a focus on small and medium enterprises (SMEs) by I. Sam Saguy, Vera Sirotinskaya, in Trends in Food Science & Technology, 2014 The food industry, and especially small and medium enterprises in that industry, are faced with numerous complex challenges that open innovation addres... »

Big Pharma, little science? ☆: A bibliometric perspective on Big Pharma’s R&D decline

Big Pharma, little science? ☆: A bibliometric perspective on Big Pharma’s R&D decline

  Biowebspin, January 28th, 2015 Big Pharma, little science? ☆: A bibliometric perspective on Big Pharma's R&D decline by Ismael Rafolsa, Michael M. Hopkins, Jarno Hoekman, Josh Siepel, Alice O'Hare, Antonio Perianes-Rodríguez, Paul Nightingale, in Technological Forecasting and Social Change, 2014 There is a widespread perception that pharmaceutical R&D is facing a productivity crisis char... »

Policy-driven ecosystems for new vaccine development

Policy-driven ecosystems for new vaccine development

  Biowebspin, January 1st, 2015 Policy-driven ecosystems for new vaccine development by Julia Fan Li, Elizabeth Garnsey, in Technovation, 2014 This paper examines the relationship between biomedical policies and entrepreneurial R&D strategies. Public health programs have been unable to provide effective and affordable treatment of infectious diseases for the poor. While governments have become... »

Open innovation: A real option to restore value to the biopharmaceutical R&D

Open innovation: A real option to restore value to the biopharmaceutical R&D

  Biowebspin, January 1st, 2015 Open innovation: A real option to restore value to the biopharmaceutical R&D by Giovanna Lo Nigro, Azzurra Morreale, Gianluca Enea, in International Journal of Production Economics, 2014 The pharmaceutical landscape has changed, and new business models, based on alliances, are increasingly being adopted in this industry. Biotechnology advances have pushed this d... »

On the management of open innovation ☆

On the management of open innovation ☆

  Biowebspin, January 1st, 2015 On the management of open innovation ☆ by Alfonso Gambardella, , Claudio Panico, in Research Policy, 2014 In an open innovation relationship, the party that owns a key asset enjoys bargaining power that discourages the investments of the other party in the collaboration. We show that these incentives can be restored by conferring on the weak party the power to take ... »

Open-Innovation Effectiveness: When does the Macro Design of Alliance Portfolios Matter?

Open-Innovation Effectiveness: When does the Macro Design of Alliance Portfolios Matter?

  Biowebspin, January 1st, 2015 Open-Innovation Effectiveness: When does the Macro Design of Alliance Portfolios Matter? by Shalini Rogbeer, Rangga Almahendra, Björn Ambos, in Journal of International Management, 2014 We determine the impact of the macro-design of a firm's alliance portfolio on its open-innovation effectiveness. Three elements of macro-design—international, technological, and part... »

Neurological drug development: A guide for a start-up biotech

Neurological drug development: A guide for a start-up biotech

  Biowebspin, January 1st, 2015 Neurological drug development: A guide for a start-up biotech by Dr. Thomas P. Blackburn, PhD, DSc, Dr. Erwan Bezard, PhD, in Neurobiology of Disease, 2014   See the article and check access: If you can't access this article, do not hesitate to contact us. »